Meijie Medical

Shanghai Meijie Medical Technology Co., Ltd. commercializes a first-of-its-kind multimodal tumor treatment technology developed through over 20 years of research at Shanghai Jiao Tong University. The company’s flagship product represents the world’s first approved multimodal tumor ablation system, integrating cryogenic freezing and radiofrequency heating technologies for enhanced cancer treatment outcomes.

Company Overview

Meijie Medical emerged as the commercialization vehicle for new cryothermal immunotherapy research led by Professor Xu Xuemin at Shanghai Jiao Tong University. The company focuses on translating academic breakthroughs in bioheat physics and tumor immunology into clinical applications. Working in close collaboration with leading medical institutions including Fudan University Shanghai Cancer Center, Meijie Medical has successfully brought next-generation ablation technology from laboratory research to regulatory approval and clinical deployment.

The company operates at the intersection of thermal physics, immunology, and minimally invasive oncology, developing precision-controlled ablation platforms that combine multiple energy modalities. This interdisciplinary approach represents a departure from conventional single-modality ablation systems, offering improved tumor control and potential systemic anti-cancer immune responses.

Core Products

Multimodal Tumor Treatment System

Meijie Medical’s primary product is a multimodal tumor treatment system that integrates liquid nitrogen cryoablation with radiofrequency heating in a single platform. The system received NMPA approval on June 9, 2023, through the Special Review and Approval Procedure for Innovative Medical Devices, making it the world’s first approved device of its kind.

The technology addresses limitations of conventional thermal ablation by precisely controlling thermal dose delivery through a proprietary process: pre-freezing target tissue to reduce impedance, followed by controlled radiofrequency heating with real-time temperature monitoring. This approach enables visualization of the ablation zone, reduces procedure time, and minimizes damage to surrounding healthy tissue.

Initial approval covered liver tumor indications. In April 2025, the system received expanded approval for lung tumor applications, broadening its clinical utility for solid tumor treatment.

Technology & Innovation

The scientific foundation of Meijie Medical’s technology stems from Professor Xu Xuemin’s pioneering work in thermal biophysics at Shanghai Jiao Tong University. Key innovations include:

Precision Thermal Dose Control: The system achieves controlled thermal transitions from cryogenic temperatures to radiofrequency heating, enabling predictable ablation zone formation. Treatment precision is reported to improve by more than 10-fold compared to conventional single-modality approaches.

Cryothermal Immunotherapy Mechanism: The ablation process is designed to induce immunogenic cell death, releasing tumor antigens and remodeling the tumor microenvironment to stimulate specific anti-tumor T-cell responses. Clinical studies demonstrated that median disease-free survival improved by 240 days compared to conventional radiofrequency ablation in advanced liver cancer patients.

Ablation Needle Engineering: Proprietary needle design overcomes gas resistance challenges for efficient phase-change heat transfer. The treatment segment features RF interference shielding for accurate real-time temperature measurement, while the non-treatment segment incorporates ultra-thin vacuum insulation to prevent collateral tissue damage.

Clinical Applications

The multimodal tumor treatment system is designed for percutaneous, minimally invasive treatment of solid tumors. Clinical applications have expanded across multiple tumor types:

Liver Tumors: The primary indication at launch, liver tumor ablation has been performed at major institutions including Fudan University Shanghai Cancer Center, where Professor Li Wentao led the first-in-human multimodal ablation procedure in June 2021.

Lung Tumors: The April 2025 indication expansion enables treatment of lung malignancies, addressing challenges posed by tumors located near blood vessels, airways, and pleura where conventional thermal ablation carries higher complication risks.

The technology has been deployed at leading Chinese medical centers including Shanghai Ruijin Hospital, Fudan University Zhongshan Hospital, and Zhejiang University Sir Run Run Shaw Hospital.

Market Presence

Meijie Medical operates primarily in the Chinese market, targeting tertiary hospitals with interventional oncology programs. The company’s multimodal ablation system positions it in the growing tumor ablation equipment segment, which complements surgical resection and systemic therapies for cancer treatment.

The product received recognition including the Shanghai Anti-Cancer Science and Technology Award First Prize and the Top Ten Projects Award at the 10th China (Shanghai) International Technology Fair.

Key Milestones

• 2020-11: Multimodal Tumor Treatment System entered NMPA Innovative Medical Device Special Review pathway
• 2021-06: World’s first multimodal tumor ablation procedure performed on liver cancer patient
• 2023-06: NMPA approval granted for liver tumor indication (Class III innovative medical device)
• 2023-07: Product officially launched, began hospital deployment
• 2024-06: Featured at 10th China International Technology Import-Export Fair
• 2025-04: NMPA approval expanded to include lung tumor indication

Frequently Asked Questions

What type of products does Meijie Medical develop?

Meijie Medical develops multimodal tumor ablation systems that combine cryogenic freezing and radiofrequency heating technologies. The company’s core product is designed for minimally invasive treatment of solid tumors, currently approved for liver and lung cancer applications in China.

Is the Multimodal Tumor Treatment System a surgical robot?

No, the system is an ablation platform rather than a surgical robot. It is a precision thermal ablation device that enables physicians to perform percutaneous tumor treatment, but it does not include robotic arms or autonomous navigation capabilities. The system provides controlled energy delivery and real-time visualization for tumor destruction.

What is the regulatory status of Meijie Medical’s products?

The Multimodal Tumor Treatment System received NMPA Class III medical device approval in June 2023 through China’s Innovative Medical Device Special Review pathway. This makes it the first globally approved system combining cryoablation and radiofrequency heating. International regulatory status (CE Mark, FDA) has not been publicly disclosed.